Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) PT at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have earned a consensus rating of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $4.79.

MRNS has been the topic of several research analyst reports. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, StockNews.com began coverage on Marinus Pharmaceuticals in a report on Wednesday, January 29th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. abrdn plc grew its holdings in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares during the period. Suvretta Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the period. Franklin Resources Inc. grew its holdings in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the period. GSA Capital Partners LLP grew its holdings in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth $727,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Down 0.1 %

MRNS opened at $0.55 on Friday. The firm has a market cap of $30.18 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $10.50. The business’s 50 day moving average is $0.42 and its two-hundred day moving average is $0.93.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.